The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Single App knock-in mouse models of Alzheimer’s disease
Abstract
Experimental studies of Alzheimer's disease have largely depended on transgenic mice overexpressing amyloid precursor protein (APP). These mice, however, suffer from artificial phenotypes because, in addition to amyloid β peptide (Aβ), they overproduce other APP fragments. We generated knock-in mice that harbor Swedish and Beyreuther/Iberian mutations with and without the Arctic mutation in the APP gene. The mice showed typical Aβ pathology, neuroinflammation and memory impairment in an age-dependent manner.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We elected to use the AppNL-G-F knock-in mouse model for this study as it expresses App under its endogenous promoter in a physiological manner with regards to both cell type and amount, and avoids the issue of APP overexpression and abnormal expression patterns.”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [33]
In the citing paper
“AppNL-G-F mice [C57BL/6-App<tm3(NL-G-F)Tcs> (No.RBRC06344)] were provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan [33].”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [33]
In the citing paper
“we employed APPNLGF knock-in mice that express a humanized and triple-mutated APP in the endogenous App locus to circumvent transgenic mouse artifacts.”
From Oligodendrocytes produce amyloid-β and contribute to plaque formation alongside neurons in Alzheimer’s disease model mice (2024) · cites this paper as [34]
In the citing paper
“While novel APP knock-in models, such as APPNL, APPNL-F, or APPNL-G-F mice overproduce Aβ1–42 in the absence of potentially confounding APP overexpression [139], these mice still contain one or more independent FAD mutations, which might result in an abnormal Aβ conformation [140].”
From Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models (2020) · cites this paper as [139]
In the citing paper
“By 6 months of age, App NL‐G‐F mice exhibit a substantial amyloid plaque burden in the brain”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Saito et al. 2014
In the citing paper
“These were bred to the App NL‐G‐F AD‐like model to determine responses in the context of amyloid‐driven pathology (Saito et al. 2014).”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Saito et al. 2014
In the citing paper
“The App NL‐G‐F mice are characterized by progressive amyloid deposition from 2 months to cognitive decline by 6 months (Saito et al. 2014).”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Saito et al. 2014
In the citing paper
“The App NL‐G‐F knock‐in model, however, has physiological App expression levels, avoiding the overexpression artifacts found in other transgenic models”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Saito et al. 2014
In the citing paper
“but is strongly biased toward very high Aβ42:40 ratios (~10–100:1) because of the familial mutations”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Saito et al. 2014
In the citing paper
“In AppNL-G-F mice, which harbor all three mutations, Aβ amyloidosis is aggressive, and neuroinflammation is observed in subcortical structures as well as cortical regions [10–12].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“By contrast, AppNL mice that carry only the Swedish mutation produce significantly higher levels of Aβ40 and Aβ42 without overt AD-related brain pathology such as extracellular Aβ plaques or neuroinflammation [10, 11, 13].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“alternative mouse models have been generated via knock-in (KI) of a humanized Aβ sequences harboring familial AD mutations (Swedish (NL), Beyreuther/Iberian (F), and Arctic (G)) in order to model Aβ amyloidosis without non-physiological overexpression of APP [10].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“By contrast, AppNL mice that carry only the Swedish mutation produce significantly higher levels of Aβ40 and Aβ42 without overt AD-related brain pathology such as extracellular Aβ plaques or neuroinflammation [10, 11, 13].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“To overcome these issues, KI mouse models with familial AD mutations have been generated [10, 24, 31, 32].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“despite overproducing human Aβ40 and Aβ42 in their brains [10, 13].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“These results are consistent with recent studies reporting negligible cognitive deficits and the lack of Aβ plaque formation in AppNL/NL mice (Fig. 6) [10, 11, 13, 14, 24].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [10]
In the citing paper
“Both models express human APP at physiological levels.”
From Integrated analysis of behavioral, epigenetic, and gut microbiome analyses in AppNL-G-F, AppNL-F, and wild type mice (2021) · cites this paper as [25]
In the citing paper
“The AppNL-G-F and AppNL-F show neuropathology and hippocampus-dependent cognitive impairments at 6 or 18 months, respectively.”
From Integrated analysis of behavioral, epigenetic, and gut microbiome analyses in AppNL-G-F, AppNL-F, and wild type mice (2021) · cites this paper as [25]
In the citing paper
“Our result in female mice is consistent with the cognitive phenotype in the Y maze reported in this genotype25,42.”
From Integrated analysis of behavioral, epigenetic, and gut microbiome analyses in AppNL-G-F, AppNL-F, and wild type mice (2021) · cites this paper as [25]
In the citing paper
“Human APP knockin (KI) models develop robust Aβ pathology, yet do not exhibit artifacts associated with APP over-expression, such as elevated levels of APP cleavage products (Saito et al., 2014).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“These studies all suffer because they exhibit artifacts arising from the over-expression APP (WT or mutant) and in some cases mutant presenilins (Balducci and Forloni, 2011; Saito et al., 2014; Sasaguri et al., 2017).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“Human MAPT knock-in models have also been developed, and these models produce tau pathology, but only very late in the murine life span (~15 months) (Saito et al., 2014; Sakakibara et al., 2018; Sasaguri et al., 2022).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“However, over-expressing APP and presenilin 1 cause effect resulting from the over-expression that are unrelated to the disease process (Saito et al., 2014; Sakakibara et al., 2018).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“These mice develop robust plaque pathology beginning as early as 3 months of age, however they develop little tau pathology and little neurodegeneration (Saito et al., 2014; Sakakibara et al., 2018).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“These patterns of labeling or Aβ and MAPT are consistent with prior studies of APPNL-G-F and P301S MAPT mice (Yoshiyama et al., 2007; Saito et al., 2014; Sasaguri et al., 2017; Apicco et al., 2018).”
From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Saito et al., 2014
In the citing paper
“As expected,15 22-month-old AppNL-G-F mice had robust AD-related pathology, including amyloid deposition and neuroinflammation (Figures 1C and 1D).”
From Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models (2024) · cites this paper as [15]
In the citing paper
“As suggested,15,20 App KI mice may model pre-clinical stages of AD, characterized by progressive amyloidosis and gliosis without prominent cognitive deterioration, tau pathology, or neurodegeneration.”
From Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models (2024) · cites this paper as [15]
In the citing paper
“Humanized App knockin (KI) and APP transgenic mouse models mimic certain aspects of AD pathogenesis, including progressive amyloidosis, gliosis, and neuroinflammation, as well as network hyperexcitability and cognitive impairment, albeit to different degrees of severity across models and paradigms.15-27”
From Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models (2024) · cites this paper as [15]
In the citing paper
“Whereas plaque deposition only increases by less than twofold between 9 and 12 months of age, it increases tenfold between 12 and 18 months (Saito et al., 2014).”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Saito et al., 2014
In the citing paper
“By contrast, NHE6 ablation led to glial activation and decreased plaque load in ApoeAPOE4 (Sullivan et al., 1997) and AppNL-F (Saito et al., 2014) double knockin mice.”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Saito et al., 2014
In the citing paper
“The AppNL-F mouse model used in our study develops plaques at 12 months (Saito et al., 2014) in the presence of murine ApoE.”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Saito et al., 2014
In the citing paper
“In AppNL-F mice, plaques can be identified as early as 9 months of age.”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Saito et al., 2014
In the citing paper
“These mice, however, do not show cognitive impairments in spatial learning tests like Morris water maze (Saito et al., 2014) (own unpublished observations).”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Saito et al., 2014
In the citing paper
“We show in a well-studied App knock-in mouse model (Saito et al. , 2014) the gradual establishment of a multicellular co-expressed gene response encompassing 57 Plaque-Induced Genes or PIGs in the microenvironments of amyloid plaques (Figure 5).”
From Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer’s Disease (2020) · cites this paper as Saito et al., 2014
In the citing paper
“App NL-G-F knock-in (Saito et al., 2014) mice express Swedish (KM670/671NL), Beyreuther/Iberian (I716F), and Arctic (E693G) mutations in the App gene under the endogenous promoter on the C57Bl/6J background.”
From Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer’s Disease (2020) · cites this paper as Saito et al., 2014
In the citing paper
“AD mice, in which APP with a humanised Aβ region containing 3 AD-related mutations (APPNL-G-F) is knocked in (49), to avoid artefacts associated with over-expressing APP, were crossed with NG2-DsRed mice in which pericytes express DsRed (19).”
From Amyloid β oligomers constrict human capillaries in Alzheimer's disease via signaling to pericytes (2019) · cites this paper as [49]
In the citing paper
“In contrast, knock-in of Swedish and Iberian mutations results in plaque development beginning at 6 months, and gliosis, synaptic alterations and memory impairment from 18 months [129].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [129]
In the citing paper
“Additional knock-in of the Arctic mutation into these mice results in more rapid pathology development including plaque development beginning at 2 months that is more widespread throughout the brain and memory impairment from 6 months [129].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [129]
In the citing paper
“In contrast, initial studies show that more physiological knock-in mouse models develop cognitive impairment many months after plaque development [129], which is more similar to humans.”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [129]
Citations
Cites
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Saido, T. C., Iwatsubo, T., Mann, D. M. A., Shimada, H., Ihara, Y., & Kawashima, S. (1995) · Neuron · doi:10.1016/0896-6273(95)90301-1 · Cited by 587
Self-citationAβ Secretion and Plaque Formation Depend on Autophagy
Nilsson, P., Loganathan, K., Sekiguchi, M., Matsuba, Y., Hui, K., Tsubuki, S., Tanaka, M., Iwata, N., Saito, T., & Saido, T. C. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.042 · Cited by 459
Self-citationSarnyai, Z., Sibille, E. L., Pavlides, C., Fenster, R. J., McEwen, B. S., & Tóth, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.26.14731 · Cited by 396
Flagged first, then by citations
Cited by
Sorted by citations
Items 1,201–1,300 of 1,333
Delvenne, A., Vandendriessche, C., Gobom, J., Burgelman, M., Dujardin, P., Nolf, C. D., Tijms, B. M., Teunissen, C. E., Schindler, S. E., Verhey, F. R. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26750363
Park, H., Shin, J., Kim, Y., Saito, T., Saido, T. C., & Kim, J. (2022) · Figshare · doi:10.6084/m9.figshare.21129966
Self-citationNuñez‐Diaz, C., Andersson, E., Schultz, N., Pocevičiūtė, D., Hansson, O., Nilsson, K. P. R., & Wennström, M. (2024) · Figshare · doi:10.6084/m9.figshare.24934406
Clayton, K. A., Delpech, J.-C., Herron, S., Iwahara, N., Ericsson, M., Saito, T., Saido, T. C., Ikezu, S., & Ikezu, T. (2021) · Figshare · doi:10.6084/m9.figshare.14267041
Self-citationTaylor, X., Clark, I., Fitzgerald, G. J., Oluoch, H., Hole, J. T., Demattos, R. B., Wang, Y., & Pan, F. (2024) · Figshare · doi:10.6084/m9.figshare.26613988
Taylor, X., Clark, I., Fitzgerald, G. J., Oluoch, H., Hole, J. T., Demattos, R. B., Wang, Y., & Pan, F. (2024) · Figshare · doi:10.6084/m9.figshare.26613970
Tok, S., Maurin, H., Delay, C., Crauwels, D., Manyakov, N. V., der Elst, W. V., Moechars, D., & Drinkenburg, W. H. I. M. (2022) · Figshare · doi:10.6084/m9.figshare.20147031
Tambaro, S., Mitra, S., Gera, R., Linderoth, B., Wahlberg, L. U., Darreh-Shori, T., Behbahani, H., Nilsson, P., & Eriksdotter, M. (2024) · Figshare · doi:10.6084/m9.figshare.26611253
Self-citationWang, T., Sobue, A., Watanabe, S., Komine, O., Saido, T. C., Saito, T., & Yamanaka, K. (2024) · Figshare · doi:10.6084/m9.figshare.26684136
Self-citationAdditional file 1 of Aβ43 aggregates exhibit enhanced prion-like seeding activity in mice
Ruiz‐Riquelme, A., Mao, A., Barghash, M. M., Lau, H. H. C., Stuart, E., Kovacs, G. G., Nilsson, K. P. R., Fraser, P. E., Schmitt‐Ulms, G., & Watts, J. C. (2021) · Figshare · doi:10.6084/m9.figshare.14570473
Andersson, E., Schultz, N., Saito, T., Saido, T. C., Blennow, K., Gouras, G. K., Zetterberg, H., & Hansson, O. (2023) · Figshare · doi:10.6084/m9.figshare.22620482
Self-citationSharoar, M. G., Palko, S. I., Ge, Y., Saido, T. C., & Yan, R. (2021) · Figshare · doi:10.6084/m9.figshare.14903780
Self-citationBenítez, D. P., Jiang, S., Wood, J. I., Wang, R., Hall, C. M., Peerboom, C., Wong, N., Stringer, K. M., Vitanova, K. S., Smith, V. C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14992867
Self-citationJiang, R., Smailović, U., Haytural, H., Tijms, B. M., Li, H., Haret, R. M., Shevchenko, G., Chen, G., Abelein, A., Gobom, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20226961
Self-citationGustavsson, T., Metzendorf, N. G., Wik, E., Roshanbin, S., Julku, U. H., Chourlia, A., Nilsson, P., Andersson, K. G., Laudon, H., Hultqvist, G., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22735600
Self-citationTaylor, X., Clark, I., Fitzgerald, G. J., Oluoch, H., Hole, J. T., Demattos, R. B., Wang, Y., & Pan, F. (2024) · Figshare · doi:10.6084/m9.figshare.26613976
Jiang, R., Smailović, U., Haytural, H., Tijms, B. M., Li, H., Haret, R. M., Shevchenko, G., Chen, G., Abelein, A., Gobom, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20226973
Self-citationBrown, J. L., Hart, D. W., Boyle, G. E., Brown, T. G., LaCroix, M., Baraibar, A. M., Pelzel, R. J., Kim, M., Sherman, M. A., Boes, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26554283
Mouse models of Alzheimer’s disease pathology
Kim, S., & Gray, N. E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29090-9.00004-0
Mouse models elucidating the role of apolipoprotein E in neurological conditions
Torres, E. R. S., & Raber, J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29090-9.00001-5
Kawakami, S., Jung, C., Inoue, R., Nakamura, T., Sato, S., & Michikawa, M. (2025) · Diagnostics · doi:10.3390/diagnostics16010061
Tisdale, R. K., Sun, Y., Miller, S. R., Lee, S. M., Park, S., Shin, J., Allocca, G., Palop, J. J., & Kilduff, T. S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.29.696818
Stas, E., Yang, M., Schultz, S. R., & Go, M. A. (2026) · Journal of Biomedical Optics · doi:10.1117/1.jbo.31.1.016004
The molecular fidelity of Aβ pathology in 5xFAD and AppNL−FPsen1P117L mice revealed by cryo-EM
Song, M., Zheng, H., Han, J., Xu, K., Zhang, D., & Cao, Q. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00924-6
Konings, S. C., Nyberg, E., Martinsson, I., Thakore, R., Gouras, G. K., & Klementieva, O. L. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.10.697647
Sánchez-Puebla, L., López‐Cuenca, I., Sánchez-Puebla, M. A., Granados, A., RAMIREZ, A., Lloréns, J., Saido, T. C., Saito, T., Nieto‐Vaquero, C., Moro, M. Á., et al. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1712480
Self-citationPrieur, M., Hemonnot-Girard, A.-L., Beck, V., Garcia, V., Phuadraksa, T., Linck, N., Leportier, M., Vignon, A., Séverac, D., Perrier, V., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.28.702259
Self-citationCell type-resolved proteomics reveals intra- and intercellular signaling in Alzheimer’s diseasePreprint
Zhang, X., Yu, K., Shrestha, H. K., Zhou, Y., Yang, J., Wang, Z., Ren, X., Chen, P.-C., Sun, H., Liu, D., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.02.703357
Vicious circle of amyloid and leptomeningeal macrophages evokes vascular dysfunction in CAAPreprint
Hartantyo, R. Y., Tsuji, T., Hou, L., Saito, R., Yamasaki, A., Kochi, T., Saito, Y., Tada, M., Cheung, D. L., Moorhouse, A. J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.12.705483
Sleep-Wake Transitions Are Impaired in the AppNL-G-F Mouse Model of Early Onset Alzheimer’s DiseasePreprint
Tisdale, R. K., Sun, Y., Miller, S. R., Lee, S. M., Park, S., Shin, J., Allocca, G., Palop, J. J., & Kilduff, T. S. (2026) · eLife · doi:10.7554/elife.110240.1
Vulnerability of short-term memory in a mouse model of Alzheimer’s disease
Li, C., Chia, X. W., Xu, G., Ang, L. F., & Makino, H. (2026) · Nature Communications · doi:10.1038/s41467-026-69619-2
Ravula, A. R., Hagita-Tatsumoto, A., Gibbs, B. J., Ray, N. B., Ellison, J. W., Longtree‐Preciado, A., Radhakishun, S., Qiao, W., Zhao, N., Saito, T., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.23.707081
Self-citationStephan, P., Plassard, D., Keyes, W. M., & Hérault, Y. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06079-3
Microglial senescence and senolytic drugs
Ben-Azu, B., Sabbah, S., Awogbindin, I. O., Chidebe, E. O., Oritsemuelebi, B., Patel, D., Frenkel, D., & Tremblay, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27340-7.00010-3
Muñoz, P., Ali, H. G., Demetriou, A., Latorre‐Leal, M., Shimozawa, M., Delac, L., Troncea‐Sandu, T., Inzunza, J., Nilsson, P., Maioli, S., et al. (2026) · Journal of Neuroendocrinology · doi:10.1111/jne.70161
Self-citationLi, D., Li, Y., Wen, L., Chen, Z., Gao, F., Shen, Y., & Wang, Q. (2026) · Neuroscience Bulletin · doi:10.1007/s12264-026-01593-7
Cho, Y.-J., Kim, S.-H., Ryu, S.-H., Chung, C., Lee, N., Kim, N. H., Jeong, M., Kim, Y.-J., Gwak, J., Choi, S.-Y., et al. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00936-2
Self-citationCools, L., Dahdouh-Guebas, Y., Kemps, I., Bergmans, S., Castelein, J., Vandenbroucke, R. E., Hoecke, L. V., & Groef, L. D. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02249-3
Neurovascular large artery dilatation increases the risk for Alzheimer's disease pathology
Simpson, D., Morrone, C. D., Wear, D., Khani, A., Liu, F., Gutierrez, J., & Yu, W. H. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107368
GLP- 1受容体シグナルはアルツハイマー病モデルマウスの反応性アストロサイトにおいてアクアポリン4の 細胞内局在を修復し、アミロイドβの排泄を促進する
佐々木, 可. (n.d.) · Institutional Repositories DataBase (IRDB) · doi:10.20569/0002002067
Rôle central des glucocorticoïdes et de leurs récepteurs dans l’étiologie de la Maladie d’Alzheimer
Canet, G. (2020) · theses.fr (ABES) · doi:10.70675/c46cedbczd8bbz4a8eza301z82de5785048c
Implication du fragment C99 dans l’avènement des phénotypes pathologiques de la maladie d’Alzheimer
Bourgeois, A. (2019) · theses.fr (ABES) · doi:10.70675/bb8ccf34zec6cz4bb6z82b4z3030b9cb28f7
Physiological and pathological roles of the amyloid precursor protein at the presynapse
Jordá-Siquier, T. (2021) · theses.fr (ABES) · doi:10.70675/3bff9a77z3935z4d28zb02bz5b454bcbc77e
Unraveling the physiopathological actions of the newly discovered Aη peptides in the brain
Mensch, M. (2020) · theses.fr (ABES) · doi:10.70675/476a3b23ze46ez4002z9ae4z91bd09be5c76
Hemonnot-Girard, A.-L. (2021) · theses.fr (ABES) · doi:10.70675/9c8a4775zd774z494ez9bbazf7566faefa8f
The Use of Localized Proteomics to Understand the Pathogenesis of Alzheimer's Disease
Pires, G. (2021) · theses.fr (ABES) · doi:10.70675/45826fd6zd2c8z4b3dz91e0za5080544cb17
Poulot-Becq-Giraudon, Y. (2024) · theses.fr (ABES) · doi:10.70675/0d7a8b92z8393z4d76z82a8z87efe0790346
Role of T-cell immunity in the pathophysiology of Alzheimer’s disease and other Tauopathies
Matta, K. (2024) · theses.fr (ABES) · doi:10.70675/cea4fe5ez67c3z4445z92f7z39af62ba059b
The role of the α7 nicotinic acetylcholine receptor in a model of amyloid pathology
Santos, D. G. (2024) · theses.fr (ABES) · doi:10.70675/b3ed4de5zcd9ez4421za129z0a05130d86b9
Rafiee, Z., Santiago, J., Andersson, E., Hansson, O., & Wennström, M. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1766448
The gut microbiota-iron-brain axis in a mouse model of Alzheimer’s diseasePreprint
Kuziak, A., Policht, A., Trojan, E., Basta‐Kaim, A., Brudecki, K., Łokas, E., Klimkowicz‐Mrowiec, A., Frydrych, J. K., Grygier, B., Stanek, M., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9066555/v1
川上, 惇., & Kawakami, S. (2026) · Institutional Repositories DataBase (IRDB)
Advances and Limitations of Rodent Models in Alzheimer’s Disease Pathogenesis and Therapeutics
Singh, A., & Duerner, L. (2026) · Science Discovery Medicine · doi:10.11648/j.sdmed.20260102.14
Animal Models of Genetically-Determined Neurodegenerative Diseases and Their Development
Konno, A., Matsuzaki, Y., & Hirai, H. (2026) · Contemporary clinical neuroscience · doi:10.1007/978-3-032-18296-8_8
Soni, N. D., Swain, A., Khokhar, S. K., Wilson, N. E., Nanga, R. P. R., Kumar, D., Bouche, E., Cao, Q., Haris, M., Wolk, D. A., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08073-6
Wind-Mark, K., Kunze, L. H., Willem, M., Palumbo, G. A., Giudici, C., Nuscher, B., Boening, G., Gildehaus, F. J., Lindner, S., Werner, R. A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104632
Early Regional Microglial Remodelling in the Hippocampus of the App NL‐G‐F Alzheimer's Model
Bevan, R. J., Minett, J. F., Smith, A. L., Figueras, A. C., & Taylor, P. R. (2026) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.70082
Fuentes‐Santamaría, V., Alvarado, J. C., Benítez-Maicán, Z., Gabaldón-Ull, M. C., Saido, T. C., Saito, T., Lenarz, T., & Juiz, J. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.25.727095
Self-citationEx vivo comparison of ACU193 and lecanemab reveals binding differences in mouse brain
Grenon, M. B., Cline, E. N., Jerecı̀ć, J., Johnson, E. A., Siemers, E., & Lemere, C. A. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71509
Tsuda, Y., Madokoro, Y., Suzuki, K., Ooba, T., Sato, T., Uchida, Y., Nagai‐Arakawa, I., Saito, T., Hara, H., Hida, H., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71531
Self-citationThakore, R., Aldén, M., Gustavsson, N., Danielson, L., Lins, L. C. R. F., Sánchez, J. D., Arensburg, A. R., Paulus, A., da Silva, I. A. N., Skoryk, V. R., et al. (2026) · Parkinson s Disease · doi:10.1155/padi/7303965
Muramatsu, I., Uwada, J., Nagai‐Arakawa, I., Matsukawa, N., & Masuoka, T. (2026) · FEBS Letters · doi:10.1002/1873-3468.70385
Tisdale, R. K., Sun, Y., Miller, S. R., Lee, S. M., Park, S., Shin, J., Allocca, G., Palop, J. J., & Kilduff, T. S. (2026) · eLife · doi:10.7554/elife.110240.2
Tisdale, R. K., Sun, Y., Miller, S. R., Lee, S. M., Park, S., Shin, J., Allocca, G., Palop, J. J., & Kilduff, T. S. (2026) · eLife · doi:10.7554/elife.110240.2.sa0
Differential A-to-I editing of SINE B2 RNAs unveils an epitranscriptome response to Aβ neurotoxicity
Mitchell, L., Saville, L., Gollen, B., Haight, T., Roy, R., Turner, C., Cheng, Y., Kovalchuk, I., Mohajerani, M. H., & Zovoilis, A. (2026) · Life Science Alliance · doi:10.26508/lsa.202603668
Pacheco-Sánchez, B., López-Gambero, A. J., Gavito, A., Rivera, P., Suárez, J., Sanjuan, C., Nilsson, P., Tambaro, S., & de Fonseca, F. R. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119629
Self-citationShirotani, K., Hatta, D., Watanabe, K., Saito, T., Saido, T. C., & Iwata, N. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.115894
Self-citationYang, T., Xu, Y. R., Li, S., Bellier, J., Tao, Y., Francis, A. E., Stern, A. M., Jin, S., Ostaszewski, B. L., Lawton, T., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117599
Chung, M. L. K., Takeda, S., Ryu, J., Murayama, S., Koshimizu, U., & Kondo, T. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261462890
Reprogramming lipid metabolism for cognitive restoration in Alzheimer's via PLA2G4E
Badesso, S., Espelosin, M., Alonso, C., Montilla, A., Collantes, M., Cuadrado‐Tejedor, M., & García‐Osta, A. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70285
Hunting for an Antigen: Humoral Immunity in Alzheimer’s Disease
Delgado, A. M., Greer, B. D., Maul, R. W., & Gearhart, P. J. (2026) · Cells · doi:10.3390/cells15131227
Acuaporina-4 y el sistema glinfático: claves en el desarrollo del Alzheimer
Pulido, E. U. R., López, J. L. H., & Nuche, M. L. (2026) · Acta Médica Grupo Ángeles · doi:10.35366/123506
Bjørnholm, K. D., Li, H., Gaudio, F. D., Mocci, G., Shao, W., Baldisseri, E., Rao, S. B., Lindblad, C., Fletcher‐Sandersjöö, A., Vázquez-Liébanas, E., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-75367-0
Self-citationGlial subcellular specialisation resolved with high resolution spatial transcriptomicsPreprint
Boulger, S. L., Melgosa-Ecenarro, L., Zielonka, M., Pilch, K. S., Wijesinghe, S. S., Radulescu, C. I., Matthews, P. M., Barnes, S. J., & Mallach, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.12.737168
Therapeutic Gene Editing of APOE4 in Sporadic Alzheimer's Disease via Prime Editor 7
Kim, Y. A., Lee, G. S., An, S., Park, H., Kim, H., Kim, J., Kang, S., Kim, S., Kwon, D., Park, J., et al. (2026) · Advanced Science · doi:10.1002/advs.76658
Mao, A., Ruiz‐Riquelme, A., Barghash, M. M., Silver, N. R. G., Lau, H. H. C., Stuart, E., Zampar, S., Sehlin, D., Syvänen, S., Pollanen, M. S., et al. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02390-z
Shirotani, K., Hatta, D., Watanabe, K., Saito, T., Saido, T. C., & Iwata, N. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.18.724708
Self-citationThe emerging role of astrocytes in spatial cognition, action and Alzheimer’s disease
Gaborit, M., Arabi, A., & Mariotti, L. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2026.1811370
Zhang, X., Zhuang, D., Lai, C., Zheng, C., Soh, Z. D., Wagner, S. K., Cai, V. Y., Yang, Z., Wang, S., Geng, X., et al. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101504
Xie, Y., Chong-Teik, L., Lam, X.-J., Cheah, P.-S., Ling, K., & Huang, T. (2026) · PLoS ONE · doi:10.1371/journal.pone.0354882
Jiang, Y., Li, Y., Xie, Q., Li, Y., & Wang, H. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.28.738702
Rawal, P., Moon, H.-J., Nguyen, V., Khatri, S., Larson, M. A., Vivian, J. C., Saido, T. C., & Zhao, L. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.30.741791
Self-citationOligodendrocyte Lineage Dysfunction in Alzheimer’s Disease: A Bidirectional, Stage-Dependent Account
Ning, X., 蓝娇, & Miao, J. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-026-01792-w
Şimşekçi, U., & Cesaretli, Y. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1882211
Nollet, M., Ba, W., Soto, B. A., Yin, C., Lignos, L., Jović, K., Wong, S., Vyssotski, A. L., Yustos, R., Franks, N. P., et al. (2026) · eLife · doi:10.7554/elife.112390
Unaran, E., Adebiyi, O. E., Krishnan, M. R., Bussey, T. J., Saksida, L. M., Prado, M. A., Prado, V. F., & Menon, R. S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.12.744193
Nollet, M., Ba, W., Soto, B. A., Yin, C., Lignos, L., Jović, K., Wong, S., Vyssotski, A. L., Yustos, R., Franks, N. P., et al. (2026) · eLife · doi:10.7554/elife.112390.1
Ono, M., Capozzi, A., Hirata, K., Yamauchi, C., Saito, K., Mishkovsky, M., & Takado, Y. (2026) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x261482014
Metadata
- Authors
- Saito, T., Matsuba, Y., Mihira, N., Takano, J., Nilsson, P., Itohara, S., Iwata, N., & Saido, T. C.
- Affiliations
- RIKEN Center for Brain Science (JP)
- Corresponding author
- Saido, Takaomi C
- Venue
- Nature Neuroscience
- Published
- 2014-04-13
- Volume
- 17
- Issue
- 5
- Pages
- 661-663
- ISSN
- 1097-6256 (ISSN-L)
- 1546-1726
- OpenAlex
- W2090620788
- Cited by
- 1,366
- References
- 26
- Citations by year
- 2026: 159 · 2025: 164 · 2024: 209 · 2023: 167 · 2022: 157 · 2021: 155 · 2020: 92 · 2019: 73 · 2018: 64 · 2017: 49 · 2016: 37 · 2015: 24 · 2014: 13
- FWCI
- 15.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (23680039, 26290019)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, knock-in mice, amyloid precursor protein, APP mutations, Swedish mutation, Arctic mutation, amyloid-beta pathology, neuroinflammation, memory impairment, age-dependent phenotype
- MeSH terms
- Age Factors, Alzheimer Disease, Analysis of Variance, Animals, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Humans, Mice, Inbred C57BL, Mice, Transgenic, Mutation, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Maze Learning, Mice, Gene Knock-In Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
